Re­searchers at City of Hope com­bine on­colyt­ic virus with a CAR-T to erad­i­cate sol­id tu­mors in mice

A new com­bi­na­tion of ex­ist­ing can­cer treat­ments is show­ing ear­ly signs of po­ten­tial­ly crack­ing open a new ap­proach to treat­ing sol­id tu­mors.

In pre­clin­i­cal re­search pub­lished by City of Hope, a Cal­i­for­nia-based non-prof­it, sci­en­tists ef­fec­tive­ly blend­ed CAR-T ther­a­py with an on­colyt­ic virus to erad­i­cate sol­id tu­mors in mice. The virus is ge­net­i­cal­ly en­gi­neered to en­ter the tu­mors and force them to ex­press the CD19 pro­tein, al­low­ing the CAR-T cells to at­tack.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.